Helix BioPharma Corp. Board Changes

RICHMOND HILL, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: HBP) (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors.

The Board has accepted the resignation of Dr. Marek Orlowski as a director of the Company.  In his place, the Board is pleased to announce the appointment of Mr. Artur Gabor to the Board.  Mr. Gabor has extensive experience in merger and acquisitions, corporate finance and restructuring. 

“On behalf of the Board and management of Helix, I would like to thank Marek for his time and dedication, and wish him well in his future endeavors,” said Slawomir Majewski, Chairman of Helix.  “In addition, we are extremely pleased in welcoming Mr. Gabor to Helix’s Board.”

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Investor Relations

Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
Email: ir@helixbiopharma.com